A new scaffold to help heal severe skin injuries
Official title: An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery
Funded at Fesariustherapeutics, INC. · NIH-10899570 · Data updated 2026-11-12
This study is testing a new skin treatment called DermiSphere™ to help people with serious skin injuries heal faster and more comfortably, without needing to use their own skin.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fesariustherapeutics, INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $953,538 |
| NIH project number | 5R44AR082787-02 |
| Project ID | NIH-10899570 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from full thickness skin loss due to burns or other severe injuries.
✕Less likely to help
Patients with superficial skin injuries or those who do not have full thickness skin loss may not benefit from this research.
What this research studies
This research focuses on developing an innovative dermal replacement scaffold called DermiSphere™ to enhance the healing process for patients with full thickness skin loss. The current treatment methods often involve using the patient's own skin, which can be limited and painful. DermiSphere™ aims to promote faster cellular infiltration and blood vessel formation, leading to quicker and more effective healing. By regenerating the dermis in less than a week, this approach could significantly improve recovery times and outcomes for patients with severe skin injuries.
Why it matters
Potential benefit: If successful, this research could provide patients with a faster and more effective healing option for severe skin injuries.
How similar studies have gone: Previous research has shown promise in developing dermal scaffolds, but DermiSphere™ represents a novel approach with the potential for significant advancements in healing times.
Where this research is happening
-
Fesariustherapeutics, INC.
New York, United States Active
Researchers
- Principal investigator: Sapir Lekhovitser, Yulia — Fesariustherapeutics, INC.
- Study coordinator: Sapir Lekhovitser, Yulia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.